Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Protocol: Axitinib and Avelumab - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Protocol: Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Protocol: Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)

New Protocol: Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma (ACC)
Study:
  • Open-label, single-arm, phase 2 study
  • Pretreated metastatic or recurrent ACC
  • Axitinib + Avelumab q28 (n=28)
Efficacy:
  • ORR: 21% [8.3%-41.0%]
  • mPFS: 7.3 mos [3.7-11.2 mos]
  • mOS: 16.6 mos [12.4-NR]
Safety:
  • Any grade AEs: Fatigue (62%), diarrhea (32%), hypertension (32%), mucositis (29%)
  • Grad≥ AEs: Hypertension (9%), fatigue (6%), palmar-plantar erythrodysesthesia (6%)

J Clin Oncol 2023; 28 MAR

Ferrarotto Renata et al. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

http://doi.org/10.1200/JCO.22.02221

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More